A confirmatory, prospective, open-label, multi-centre phase 3 study to evaluate diagnostic performance of 89Zirconium-labelled girentuximab(89Zr-TLX250) to non-invasively detect clear cell renal cell carcinoma (ccRCC) by positron emission tomography/CT (PET/CT) imaging in patients with indeterminate renal masses (ZIRCON study)

  • Gurney, Howard (Primary Chief Investigator)
  • Butala, Radhika, (Other)
  • Cunningham, Jacob, (Other)

Project: Other

Project Details

AcronymZIRCON
StatusActive
Effective start/end date31/10/1818/10/23